nasal polyp. Polyp of nasal cavity
Conditions
Interventions
Intervention group:Participants in the intervention group receive intranasal injections of autologous platelet-rich plasma (PRP), prepared from each participant’s own blood and administered at the des
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: People who have been diagnosed with nasal polyps by a doctor and can use these drops in addition to routine treatments.
Exclusion criteria
Exclusion criteria: People who, in addition to nasal polyps, have other diseases such as asthma or nose and throat infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is the change in nasal polyp size and severity following treatment with the study nasal drops. This variable reflects the therapeutic efficacy of the intervention and includes reduction in polyp volume, improvement in nasal obstruction, and alleviation of associated symptoms. Timepoint: Baseline (before starting treatment)•2 weeks after treatment initiation•4 weeks after treatment initiation•8 weeks after treatment (for long-term follow-up, if applicable). Method of measurement: •Clinical assessment using nasal endoscopy and scoring of polyp size according to standardized scales such as the Lildholdt scoring system.•Documentation of endoscopic images and approximate polyp volume measurement.•Patient-reported symptom scoring (e.g., nasal obstruction, rhinorrhea, and olfactory dysfunction) using validated questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmehdi torabizadeh
Ahvaz University of Medical Sciences
Outcome results
None listed